Navigation Links
Soligenix to Present at 12th Annual BIO CEO & Investor Conference
Date:2/3/2010

cts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including RiVax™,  SGX201, orBec® and LPMTM, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is de
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Reports Third Quarter 2009 Financial Results
2. Soligenix to Present at 8th Annual BIO Investor Forum
3. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
4. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
5. Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
6. ERT to Present at the UBS 20th Annual Global Healthcare Services Conference on February 8, 2010
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
9. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
10. NeurogesX to Present at J.P. Morgan Health Care Conference
11. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Calif. , April 1, 2015  ValGenesis Inc., ... solutions, announced today that it has completed its Service ... 101, Attest Engagements (AICPA, Professional Standards) for the period ... st 2014.  ... The SOC ...
(Date:4/1/2015)... Mass. , April 1, 2015  EMD Serono, ... Germany , announced today the appointment of ... Medical Affairs, Neurology and Immunology. In this capacity, he ... and business development projects and collaborations for Rebif ® ... and Neurology pipeline. Dr. Munschauer joins ...
(Date:4/1/2015)... FORT LAUDERDALE, Fla. , April 1, 2015 /PRNewswire/ ... nothing at all about oral cancer (68 percent) and ... at their last dental check-up, according to findings from ... Inc. ("Vigilant"), a leading innovator and developer of ... of cancer. The online survey polled 1,050 ...
(Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... addition of the "Forensic Technologies and Services ... their offering. This report analyzes the ... US$ Million by the following Segments: Forensic Databases, ... and Others. Annual estimates and forecasts ...
Breaking Biology Technology:ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 3Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 4Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 5Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 6Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 7
... AMSTERDAM, August 17 SynCo Bio Partners, ... a strategic partnership to produce Versartis, lead drug candidate,VRS-859, ... type 2 diabetes,Under the agreement, SynCo will further develop ... manufacturing process to,increase yields for the forthcoming cGMP production. ...
... , , , ... BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading manufacturer ... today announced that it has entered into a non-exclusive distribution ... STEMCELL Technologies, a member of the StemCell Group of companies, ...
... MD, and Christchurch, NZ June 25, 2009 ... detection solutions, today reported that new independent data to ... the exceptional accuracy of its Ceeker (pronounced "seeker") portable ... similar-looking hoax substances. The data show that in ...
Cached Biology Technology:SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 2BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement 3Novel handheld device detects anthrax with outstanding accuracy and reliability 2Novel handheld device detects anthrax with outstanding accuracy and reliability 3
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... In a first-of-its-kind clinical trial, physician-scientists at University Hospitals ... Western Reserve University School of Medicine are studying a ... five-year study is recruiting patients to compare the effectiveness ... large colon polyps. SDNA is a ...
... geneticist Alexander Varshavsky (California Institute of Technology, USA), who was ... 1977, has been awarded the Otto Warburg Medal of the ... is considered to be the highest German award for biochemists ... carried out with yeast and cell cultures of higher organisms, ...
... addition to being among his most vibrant and celebrated works, ... mutation whose genetic basis has, until now, been a bit ... (March 29) in the journal PLoS Genetics , however, ... behind the distinctive, thick bands of yellow "double flowers" that ...
Cached Biology News:New clinical trial explores novel noninvasive colon cancer screening test 2New clinical trial explores novel noninvasive colon cancer screening test 3Otto Warburg Medal for Alexander Varshavsky 2Otto Warburg Medal for Alexander Varshavsky 3UGA scientists reveal genetic mutation depicted in van Gogh's sunflower paintings 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... Spectrometer, utilizing many of the high-end ... high throughput and excellent productivity, providing ... Like the GCMS-QP2010 Plus, the GCMS-QP2010s ... optimum separation, 20 temperature ramps, and ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... a single-channel sample processing head, an 8-channel ... dispenser all in one compact, affordable product. ... tips, the Precision XS autoclavable and organic ... for transferring larger volumes. Intuitive Precision Power ...
Biology Products: